Optimization of Epigenetic Modifier Drug Combination for Synergistic Effect against Glioblastoma Multiform Cancer...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
• Epigenetic therapies, particularly synergistic drug combinations, show promise for treating aggressive solid tumors like GBM.

Purpose of the Study:

• To optimize synergistic combinations of epigenetic drugs for enhanced glioblastoma treatment.
• To investigate the effects of optimized drug combinations on GBM cell lines U87 and U251.

Main Methods:

• Response Surface Methodology (RSM) was employed to optimize drug combinations.
• U87 and U251 glioblastoma cell lines were treated with SAHA, 5-Azacytidine, GSK-126, and PTC-209 individually and in optimized combinations.
• Cell survival, cell cycle arrest, apoptosis, and protein expression (cyclin B1, cyclin D1, caspase-3) were analyzed.

Main Results:

• Optimized synergistic drug combinations significantly reduced GBM cell survival.
• The combinations effectively induced cell cycle arrest and apoptosis in both U87 and U251 cell lines.
• Key protein expressions were altered: decreased cyclin B1 and cyclin D1, increased caspase-3.

Conclusions:

• RSM optimization identified effective synergistic epigenetic drug combinations for GBM.
• These optimized combinations demonstrate significant anti-cancer effects, including reduced cell survival and induced apoptosis.
• Epigenetic therapy holds potential for aggressive glioblastoma treatment.